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Abstract
Background: Cluster headache (CH) is considered the most excruciating primary headache syndrome; although
much less prevalent than migraine, it is not rare as it affects more than 1/1000 people. While its clinical
presentation is considered stereotypic, atypical features are often encountered. Internationally, cluster headache is
often misdiagnosed, undertreated and mistreated.
Methods: We prospectively studied 302 CH patients, all examined by the same headache specialist. The aim of our
study was to describe the demographic and clinical characteristics of CH patients in Greece and draw attention to
under-management, under-treatment and mis-treatment often encountered in clinical practice; our purpose is to
improve recognition and successful treatment of cluster patients by Greek neurologists and other physicians.
Results: In the present cohort, clinical characteristics of CH are similar to those described in other populations.
Beyond the standard clinical characteristics, features like side shifts (12.6 %), location of maximal pain intensity
outside the first trigeminal branch division (10.2 %), lack of autonomic features (7 %), presence of associated
features of migraine and aggravation by physical activity (10 %) were encountered. Four out of five patients had
consulted a physician prior to diagnosis. The median number of physicians seen prior to diagnosis was 3 and the
median time to diagnosis was 5 years, though it improved for patients with recent onset. Chronic cluster headache,
side shifts, pain location in the face or the back of the head and aggravation by physical activity were found,
among others, to be statistically significantly related to delayed diagnosis or more physicians seen prior to
diagnosis. Even properly diagnosed patients were often undertreated or mistreated.
Conclusions: Cluster headache, in a large cohort of Greek patients, has the same phenotypic characteristics as described
internationally. Uncommon clinical features do exist and physicians should be aware of those, since they may eventuate
in diagnostic problems. Most CH patients in Greece remain misdiagnosed or undiagnosed for rather lengthy periods of
time, but time to diagnosis has improved recently. Even after diagnosis, treatment received was suboptimal.
Keywords: Cluster headache, Episodic cluster headache, Chronic cluster headache, Cluster headache phenotype, Cluster
headache demographics, Error, Delay, Misdiagnosis, Mismanagement, Mistreatment
* Correspondence: mvikelis@headaches.gr
1Headache Clinic, Mediterraneo Hospital, Glyfada, Greece
2Glyfada Headache Clinic, 8 Lazaraki Str, Glyfada 16675, Greece
Full list of author information is available at the end of the article
The Journal of Headache
                           and Pain
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Vikelis and Rapoport The Journal of Headache and Pain  (2016) 17:88 
DOI 10.1186/s10194-016-0683-0
Background
Cluster headache (CH), the most common trigeminal
autonomic cephalalgia, is considered to be the most
excruciating form of primary headache, causing profound
ictal disability to sufferers [1, 2]. Although cluster
headache was described long ago by a variety of names,
systematic study of its clinical characteristics and signifi-
cant advances in understanding its pathophysiology, began
taking place only in the last 40–50 years, pioneered by the
work of Dr. Lee Kudrow [3, 4]. He studied oxygen
inhalation therapy as a way to abort attacks; the import-
ance of light and flying through time zones as triggers;
and predicted that the hypothalamus was a critically
important area of the brain involved in its pathophysiology
[3, 4]. From a clinical, pathogenic and therapeutic point of
view, CH is distinct from other primary head syndromes
such as migraine [1–6]. Cluster headache attacks are
stereotypical and the usual clinical characteristics include
side-locked pain episodes that are accompanied by ipsilat-
eral cranial autonomic symptoms, most often lacrimation,
conjunctival injection and rhinorrhea. The attacks are
relatively short-lasting, usually 45–90 min and may differ
in duration, frequency, intensity of pain and presence of
autonomic symptoms [1–7]. Cluster headache is well
described and characterized within the International
Classification of Headache Disorders and may be diag-
nosed as episodic or chronic, the latter one characterized
by CH attacks for more than a year with no remission or
with remission for less than a month [8]. The disorder is
more prevalent in men, although the male to female varies
across studies [9].
Although often described by the word “rare” [10], CH
is not actually rare, as its prevalence in population-based
samples is estimated to be about 1/1000 [9], which is
comparable to that of multiple sclerosis [11]. Still,
worldwide, CH is considered to be largely underdiag-
nosed and undertreated, as a significant percentage of
CH patients are not treated according to existing guide-
lines or evidence-based treatment recommendations
[12, 13].
Characteristics of CH patients in various countries
[7, 14–17] and diagnostic and therapeutic trends and
issues [7, 18–21] have been described in a number of
publications, but so far no epidemiologic data have
been published from Greece. We prospectively studied
a large number of CH patients visiting two specialized
headache clinics, located in Glyfada, Greece, and exam-
ined by the same headache specialist. The aim of our
study was to describe the demographic and clinical
characteristics of CH patients in Greece; in so doing, we
hoped to draw attention to under-management and
under-treatment often encountered in clinical practice,
with the purpose of improving recognition and successful
treatment by Greek neurologists and other physicians.
Methods
This study was a prospective clinical study, conducted in
accordance with the principles of the Helsinki Declaration.
Written informed consent was obtained from every
patient. The study was approved by the first author’s Insti-
tutional Review Board (Mediterraneo Hospital, protocol
no. 1640). Data on consecutive CH patients (n = 302) were
prospectively recorded in Glyfada Headache Clinic and in
Mediterraneo Hospital Headache Clinic from February
2007 until June 2015. Patients came from all geographical
regions of Greece, mainly through self-referral (84.7 %),
although we did get referrals from other physicians, includ-
ing neurologists. All patients were examined by the same
headache specialist (MV). A detailed history was obtained
through a semi-structured questionnaire, a complete
neurological examination was performed, further examina-
tions assessed or requested when needed and patients were
finally assigned a diagnosis according to the International
Headache Society (IHS) diagnostic criteria. After the
publication of the last version of the International Classifi-
cation of Headache Disorders (ICHD-III beta) [8], all
previous cases were revisited and the IHS-III beta criteria
were used for reconfirming diagnosis. All data were
inserted in a database, double-checking for typing errors.
Only data from patients diagnosed with cluster headache
according to the IHS-III beta criteria (digit codes 3.1.1 and
3.1.2) were entered into the database and further analyzed.
X2 test of independence or Fisher’s exact test was used to
evaluate the association between two qualitative variables.
Kruskal-Wallis or Mann-Whitney test was used to evaluate
the association between groups and the continuous charac-
teristics of the sample (eg. age, etc.). Nominal variables are
presented in absolute and relative (%) frequencies, while
continuous variables are presented by median and range or
mean and standard deviation. The 5 % significance level
(alpha = 0.05) was considered as statistically significant. All
statistical analyses were performed with version 20 of the
SPSS package (SPSS Inc, Chicago, Il, USA).
Results
Demographics and CH types
Our cohort is comprised of 302 Greek patients with
cluster headache. The mean duration of follow up was
28.4 months. As expected, CH was more common in
men than in women; 237 of our patients (78.5 %) were
men while 65 (21.5 %) were women, resulting in a male-
to-female ratio of 3.6:1. Most patients were diagnosed
with episodic cluster headache (ECH) (234/302, 77.5 %).
Chronic cluster headache (CCH) was diagnosed in 68/
302 (22.5 %). Women accounted for 21.4 % in the ECH
group and 22.1 % in the CCH group, resulting to a
similar male-to-female ratio in both groups. The male to
female ratio was found to decrease with the decade of
onset, from 6:1 for onset before 1989, to 4.3:1 for onset
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between 1990 and 1999, 4.2:1 for onset from 2000 to
2009 and 2.3/1 for onset since 2010, though this change
did not reach statistical significance (p = 0.139) (Table 1).
CH family history and social habits
A positive family history of CH was reported by 17.5 % of
patients (16.7 % in ECH and 20.6 % in CCH) and in most
cases involved a parent with similar symptoms (usually
undiagnosed, but with typical witnessed clinical descrip-
tion). Smoking was quite common, with the majority of
our patients reporting being current (61.3 %) or past
smokers (12.9 %). Current alcohol consumption was
reported by 58.3 % of the patients, while 16.9 % of them
were former alcohol users. Alcohol was reported as a
trigger for CH attacks by 84,8 % of males and 45,3 % of
females (p = 0.001). Use of recreational illegal substances
was reported by 14.9 % as current and by 15.6 % as prior.
Most of CH patients in our series worked on a regular
basis (or were full-time students) (63 %), but 21 % were
unemployed and 16 % worked occasionally.
CH onset and course
The median age at onset of CH in our series was 29 years
of age (mean: 32 years), with the youngest patient report-
ing disease onset at the age of 8 and the oldest at the age
of 67 (both were ECH patients). In the ECH group,
median age of onset was 29 years (mean 31.5 years), while
in the CCH group, the median age of onset was 30 years
(mean 33.2 years). The youngest and oldest age at onset
was 8 and 68 years for men and 12 and 67 years for
women, respectively. In CCH the youngest reported age of
onset was 13 years and the oldest was 66 years of age. In
ECH, the vast majority started as episodic, but 8 patients
out of 234 (3.3 %) evolved from an initially chronic form.
In CCH, 50 out of 68 patients (73.5 %) patients experi-
enced CCH since onset, while in 18 of them (26.5 %) CH
evolved from an initially episodic form.
Clinical features
Pain location
In our cohort, pain was reported to localize in various
areas, including the orbital, supraorbital and temporal
area, but also the occiput, the upper and lower teeth, the
jaw, the nose, the cheek, the neck, the ear, the shoulder
and the vertex (Table 2). Still, the orbital, supraorbital
and temporal areas were most commonly involved (in
91.7, 56.6, and 75.5 % of patients, respectively) with
48 % of our patients reporting pain in all three of these
areas. It is worth mentioning that 5 patients were
excluded from this analysis as they reported no pain in
any of these three areas and as such they did not fulfill
criterion B of the International Headache Society [8].
They were otherwise typical CH patients. The majority
of our patients reported maximal pain intensity in the
orbital, supraorbital and temporal area (68.5, 7.3 and
13.6 %, respectively), as typically described. It should be
noticed however that additional areas, rather atypical for
maximal pain intensity, have been occasionally reported,
such as the occiput (4 % of the group), the vertex (1 %
of the group), the upper teeth (2 % of the group) and the
cheek (2.6 % of the group), while 2 patients had maximal
pain intensity in the neck and one in the jaw. No signifi-
cant differences in the areas involved were noticed
between men and women, except for the temporal area,
which was more frequently involved in men (P = 0.048).
Finally, the neck, shoulder and vertex as pain localiza-
tions were significantly more frequently reported in the
CCH group (p = 0.02, 0.001 and 0.01, respectively) as
compared to the ECH group (Table 2).
Side of pain, laterality, side shifts
While the majority of our patients experienced strictly
unilateral pain (87.4 % of total, right sided 47.0 % and left-
sided 40.4 %) without a side shift, 12.6 % reported at least
one type of a side shift, most commonly a side shift be-
tween bouts (9.0 %), followed by side shift within bouts
(3.0 %) and side shift within attacks (1.7 %). In the sub-
group of episodic cluster headache, 0.9 % had experienced
a side shift within an attack, 2.1 % had experienced a side
Table 1 Male to female ratio by decade of onset
Decade of
onset
Males
(N = 237)
Females
(N = 65)
Male to
female ratio
<1989 26 4 6
1990–1999 56 13 4.3
2000–2009 100 24 4.2
2010-present 55 24 2.3
Table 2 Site of pain (%, N = 302, unless otherwise indicated)
Total ECH CCH Men Women
Orbital (%) 91.7 92.3 89.7 93.2 86.2
Supraorbital (%) 56.6 56.4 57.4 56.1 58.5
Temporal (%) 75.5 75.2 76.5 78.1* 66.2*
Occiput (%) 45.0 45.7 42.6 47.3 36.9
Upper teeth (%) 26.2 24.4 32.4 26.2 26.2
Lower teeth (%) 12.3 11.5 14.7 12.2 12.3
Jaw (%) 18.5 17.9 20.6 20.7 10.8
Cheek (%) 24.2 21.8 32.4 26.6 15.4
Nose (%) (N = 299) 10.0 9.5 11.8 10.6 7.8
Ear (%) (N = 301) 10.0 9.9 10.3 9.3 12.5
Neck (%) 15.9 13.2* 25.0* 16 15.4
Shoulder (%) (N = 300) 6.7 3.9* 16.2* 7.2 4.7
Vertex (%) (N = 293) 24.7 21.5* 36.9* 23.9 28.6
*Indicates statistically significant difference between two groups (see text for
exact p value)
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shift within a bout and 10.4 % had experienced a shift be-
tween bouts (shift to the other side at the beginning of a
new bout). In the CCH group, side shift within attacks
was reported by 4.4 % of patients, while side shift within
bouts was reported by 5.9 % and side shift between bouts
by 4.4 % of patients (when periods of remission were re-
ported in the history of a CCH patient, Table 3). One sin-
gle patient that evolved from episodic to chronic cluster
headache later in the course of his disease developed a
side shift between attacks and subsequently a side shift
within attacks. During the within-attack side shifts, the
pain was reported to be simultaneously present in both
the right and left orbital and supraorbital area, at high in-
tensity, accompanied by bilateral autonomic features, a
characteristic that has been previously reported in other
CCH patients [17]. Side shift within attacks and within
bouts was more frequently reported in the CCH than in
the ECH group while any type of side shift was more com-
mon in men that in women, although the differences iden-
tified did not reach statistical significance (Table 3).
Autonomic and associated features, character of pain
The most commonly reported autonomic feature was
lacrimation, followed by nasal congestion/rhinorrhea and
conjunctival injection (detailed percentages in Table 4). It
should be noted that 21 patients (7 % of total) in our
cohort had none of the autonomic features listed in the
criterion C1 of the ICHD-III beta [8]. Absence of auto-
nomic features was more prevalent in women that in men
(4.6 % of males vs. 15.4 % of females had no autonomic
features, p = 0.003). Patients with no autonomic features
tended to have disease onset at an older age than those
with at least one autonomic feature (median age of disease
onset 43 vs. 29 years, but this difference did not reach
statistical significance; p = 0.064). In between sex compari-
son, lacrimation and conjunctival injection were less
frequently reported in women than in men (p = 0.031 and
p = 0.026, respectively), while no differences were noticed
between ECH and CCH. It is also worth mentioning that
autonomic features added in criterion C of ICHD-III beta
for CH, namely ipsilateral sensation of fullness in the ear
and ipsilateral forehead/facial flushing, were rather com-
monly reported in our group, by 28.1 and 27.1 % of pa-
tients, respectively (data available only for a third of total
group) (Table 4). Despite that, there was not a single case
of a patient without presence of any of the autonomic
features included in the ICHD-II (conjunctival injection
and/or lacrimation, nasal congestion and/or rhinorrhea,
eyelid oedema, forehead and facial sweating) in whom
forehead and facial flushing or sensation of fullness in the
ear was reported. Associated features considered typical
for migraine but often disregarded in CH were also quite
common (Table 5). Among them, photophobia was the
Table 3 Side of pain, laterality, side shifts (%, N = 302, unless
otherwise indicated)
Total ECH CCH Men Women
Strictly unilateral (%) 87.4 86.3 91.1 86.4 90.8
Strictly left (%) 40.4 39.7 42.6 40.9 38.5
Strictly right (%) 47.0 46.6 48.5 45.6 52.3
Side shift between bouts (%)
(N = 299)
9.0 10.4 4.4 9.8 6.2
Side shift within bouts (%)
(N = 301)
3.0 2.1 5.9 3.4 1.5
Side shift within attacks (%) 1.7 0.9 4.4 2.1 0.0
Table 4 Autonomic features (%, N = 302, unless otherwise
indicated)
Total ECH CCH Men Women
Lacrimation (%) 82.8 83.3 80.9 85.2* 73.8*
Conjunctival injection (%) 66.9 64.5 75.0 70.0* 55.4*
Nasal congestion and/or
rhinorrhea (%)
77.1 78.1 73.5 78.8 70.8
Eyelid oedema (%) 35.4 35.5 35.3 36.7 30.8
Forehead and facial
sweating (%)
19.2 20.5 14.7 198 16.9
Miosis and/or ptosis (%) 34.6 34.8 33.8 36.4 27.7
None of the above (%) 7.0 6.4 8.8 4.6* 15.4*
Forehead and facial flushing (%)
(N = 133)
27.1 26.9 27.6 26.9 27.6
Sensation of fullness in the ear (%)
(N = 128)
28.1 28.3 27.6 27.3 31.0
*Indicates statistically significant difference between two groups (see text for
exact p value)
Table 5 Associated features and character of pain (%, N = 302,
unless otherwise indicated)
Total ECH CCH Men Women
Photophobia (%) 61.6 60.3 66.2 61.6 61.5
Phonophobia (%) 36.8 34.6 44.1 38.0 32.3
Nausea (%) 22.8 22.2 25.0 23.6 20.0
Vomiting (%) (N = 301) 7.0 6.9 7.4 7.6 5.7
Belching (%) (N = 300) 21.0 21.0 20.9 22.0 17.2
Yawning (%) 19.5 18.4 23.5 21.1 13.8
Sense of restlessness or
agitation (%) (N = 301)
83.4 82.8 85.3 85.7 75.0
Pain aggravation by physical
activity (N = 301)
10.0 9.9 10.3 8.5 15.4
Stabbing/lancinating pain (%) 88.7 90.6* 82.4* 89.9 84.6
Throbbing pain (%) 7.3 6.4* 10.3* 7.6 6.2
Pressing pain (%) 1.3 1.7 0.0 1,3 1.5
Other type of pain (%) 2.6 1.3* 7.4* 1.3 7.7
Attacks triggered by alcohol
(n = 301)
76.4 74.7 82.4 84.8* 45.3*
*Indicates statistically significant difference between two groups (see text for
exact p value)
Vikelis and Rapoport The Journal of Headache and Pain  (2016) 17:88 Page 4 of 10
most prevalent (61.6 %) in our cohort and, when present,
in most patients it was reported to be lateralized to the
suffering side. Phonophobia, nausea and vomiting were
also reported (Table 5). In addition, yawning and belching
just preceding or during the final phase of an attack were
reported by approximately one out of five patients.
Another CH characteristic that is included in the IHS
classification criteria, a sense of restlessness or agitation
during attacks, was reported by 83.4 % of our patients and
was less common in women than in men (75 % vs. 85.7 %,
p = 0.042). However, It should be noted that 10.0 % of our
group reported pain aggravation by physical activity and
the majority of them preferred to stand still or lay down
during attacks. This represents a quite atypical feature,
compared to classical cluster headache descriptions. The
character of pain, as expected, was described as lancinat-
ing or stabbing in the vast majority of patients, followed
by throbbing or pressing pain (Table 5). Patients with
CCH had a lower percentage of stabbing/lancinating pain
(82.4 %) in comparison to those with ECH (90.6 %) and a
higher percentage of throbbing pain (10.3 % vs. 6.4 %) and
any other kind of pain (mainly burning pain) (7.4 % vs.
1.3 %) (p = 0.019 for these comparisons).
Attack duration and frequency, bout duration, periodicity
Some characteristics of CH, including attack duration
and frequency, may vary within the same patient during
a cluster period. Shorter or less frequent attacks may be
encountered at the beginning or ending of a bout and
longer and more frequent attacks at the peak. in order
to better describe the clinical features, we recorded not
only the usual or typical duration or frequency of attacks
but also the usual minimum and maximum values for
those. The median usual duration of attacks was 60 min
for both ECH and CCH patients, while the median usual
minimum attack duration was 40 min (45 for ECH and
30 for CCH, respectively, p = 0.009), and the median
usual maximum attack duration was 90 min (for both
ECH and CCH). It should be noted that in some patients
maximum attack duration in individual attacks exceeded
180 min and reached up to 420 min (Table 6). The me-
dian number of attacks per day was 1 (1 for ECH and 2
for CCH, p = 0.001), while the median usual maximum
number of attacks per day was 3, 2 and 3.5 for total
group, ECH and CCH, respectively (p = 0.001 for ECH
vs. CCH). The median number of bouts per year was 1
(range: 0.1–6). The median usual duration of bouts for
ECH was 4 weeks (range: 1–24 weeks). Seasonal propen-
sity of bout onset for ECH was reported by 46.2 % pa-
tients in our cohort, while a daily propensity of attack
onset (mainly nocturnal) was reported by 47 % of total
cohort and was significantly more common in ECH than
CCH (53.8 % vs. 23.5 %, p = 0.001).
Diagnostic and therapeutic issues
In the majority of our patients (175/302) a diagnosis of
CH had not been previously made and was established
during consultation at our Center for the first time.
Among the 127 previously diagnosed patients, most of
them were diagnosed by a neurologist (70.2 %), followed
by a primary care physician, neurosurgeon and ENT
specialist, (5.6, 4.8, 3.2 % respectively). Overall, 87.4 % of
patients were diagnosed by a neurologist, including
patients diagnosed at our clinic. Interestingly, 39 cases
(12.9 % of total), reported a self-diagnosis, primarily
through information found on the internet, with subse-
quent medical confirmation. In the majority of these
cases, one or more erroneous diagnoses had been made
by physicians previously. Hence, self-diagnosis was the
second more common way of diagnosis, a fact indicating
the importance of medical information provided to public.
The median time from disease onset to diagnosis in our
cohort was 5 years (range 0–45, mean 7.2 years). Overall,
time to diagnosis significantly improved with decade of
onset, for the current decade being just one year (median),
compared to 5 years for the 2000s, 12 years for the 1990s
and 20 years for onset before 1990 (Table 7). This also
Table 6 Attack duration and frequency
Total group ECH CCH Males Females
Median (range) Mean (SD) Median (range) Median (range) Median (range) Median (range)
Usual attack duration (min) 60 (20–180) 66.7 (35.3) 60 (20–180) 60 (20–180) 60 (20–180) 60 (25–180)
Usual minimum attack duration (min) 40 (5–180) 44.3 (30.5) 45* (10–180) 30* (5–90) 40 (5–180) 30 (10–180)
Usual maximum attack duration (min) 90 (30–420) 109.1 (67) 90 (30–420) 90 (30–300) 90 (30–420) 90 (30–300)
Usual attack frequency/24 h 1 (1–6) 0.9 (0.6) 1* (0.5–6) 2* (0.3–8) 1 (0.3–8) 1 (0.5–6)
Usual maximum attack frequency/24 h 3 (0.5–10) 2.9 (1.7) 2* (1–10) 3,5* (0.5–9) 3 (1–9) 3 (0.5–10)
Usual bout duration (weeks) 6 (1–52) 16.1 (19) 4 (1–24) - 7 (1–52) 6 (1–52)
Usual minimum bout duration (weeks) 4 (0.5–52) 12.8 (17) 4 (0.5–24) - 4 (1–52) 4 (1–52)
Usual maximum bout duration (weeks) 8 (0–52) 16.6 (17.7) 8 (0–50) - 8 (1–52) 8 (1–52)
*Indicates statistically significant difference between two groups (see text for exact p value)
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applied to all subgroups (males, females, ECH and CCH)
(p = 0.001 for all comparisons between subsequent de-
cades, applies also to all subgroups).
In 245/302 patients (81.1 % of total group), medical
consultation was sought prior to the diagnosis of CH. In
more detail, before being diagnosed, 63.5 % of the total
cohort had consulted a primary care physician (general
practitioner or internist, in Greece), 35.5 % an ENT
specialist, 31.4 % an ophthalmologist, 25.9 % a dentist,
41.3 % a neurologist and 8.5 % a neurosurgeon, without
having received a diagnosis of CH. Half the patients in
our cohort (51 %) had been diagnosed as migraineurs
prior to CH diagnosis, 42.3 % as suffering from trigemi-
nal neuralgia, 11 % as suffering from ophthalmic disease,
25.1 % received an ENT disease diagnosis, 15.1 % a den-
tal problem/temporomandibular joint disorder diagnosis
and 12 % a cervical spine disorder diagnosis (Table 8).
The median number of physicians seen prior to diagno-
sis was 3 (range 0–15, mean 3.5) and significantly
improved with decade of onset, from a median of 7 doc-
tors seen prior to diagnosis for onset before 1989 to a
median of 5, 3 and 1 for onset between 1990–1999,
2000–2009 and after 2009, respectively (p = 0.001 for all
comparisons). Patients with CCH had seen a larger
number of physicians prior to diagnosis than ECH
sufferers (median 4 vs. 2, p = 0.0001), while number or
physicians prior to diagnosis did not differ between
males and females (median 3, in both cases).
Although time to diagnosis and number of physicians
seen prior to diagnosis improved over time, we further
investigated whether certain disease characteristics that
were encountered less often or features that are consid-
ered atypical resulted in diagnostic delays. Factors identi-
fied as significantly correlated with greater number of
years lapsed to diagnosis included earlier decade of onset,
presence of side shift between bouts, pain location in the
jaw, cheek, lower teeth or ear area, presence of photopho-
bia, forehead and facial sweating, pain aggravation by
physical activity and absence of typical cluster headache
autonomic features (exact p values presented at Table 9).
In addition, factors associated with a greater number of
physicians prior to diagnosis included presence of CCH,
earlier decade of onset, pain location in upper teeth,
cheek, lower teeth, neck, nose, ear, shoulder or vertex,
presence of eyelid oedema, miosis/ptosis and aggravation
by physical activity (exact p values presented at Table 10).
Furthermore, increased usual and maximum duration of
bouts and increased usual and maximum attack frequency
were also correlated with seeing a larger number of physi-
cians prior to diagnosis, though these correlations were
weak (Table 10).
Cluster headache patients can be treated with
evidence-based or guideline-recommended treatments
[10, 13, 22–26], but mistreatment is often reported [19–21]
and treatments that are proven as not effective, as in the
case of indomethacin [27] or single high dose steroids [28],
or have unconfirmed efficacy, as in the case of octreotide
[29] are internationally often used. Use of inappropriate
treatments or procedures or lack of recommendation of
appropriate treatment was often encountered in our cohort,
not only in undiagnosed patients but, importantly, also in
patients previously diagnosed. Among the total group, 188
patients (62.7 %) had received pharmaceutical treatment of
any type prior to CH diagnosis and 42 patients (14.0 %) had
undergone unnecessary procedures, mainly by dentists
(10.2 %) and ENT specialists (9.9 %), most commonly tooth
extractions, fillings, sinus washout or surgery for nasal
septum deviation, in all cases without success. In a single
patient with severe cheek/ jaw pain, all teeth on the upper
jaw ipsilateral to pain had been extracted. Among the 127
previously diagnosed patients, only a minority had been of-
fered treatment with subcutaneous sumatriptan or high flow
oxygen for acute attacks or verapamil, corticosteroids or
Table 7 Years from disease onset to diagnosis, correlated to decade of onset
Tota
Median (range)
ECH
Median (range)
CCH
Median (range)
Men
Median (range)
Women
Median (range)
Decade of onset of CH
< 1989 20 (0–45) 18 (0–45) 30 (20–30) 18 (0–41) 23 (20–45)
1990–1999 12 (2–21) 11 (2–21) 13 (2–16) 12 (3–21) 12 (2–16)
2000–2009 5 (0–14) 5 (0–14) 5 (0–12) 5 (0–12) 3 (0–14)
2010-present 1 (0–7) 1 (0–7) 1 (0–6) 0 (0–6) 3 (0–7)
p = 0.001 for all comparisons between subsequent decades, applies also to comparisons between subgroups
Table 8 Diagnoses made and physicians seen prior to CH
diagnosis
A. Diagnoses made prior
to CH diagnosis (%)
B. Physicians seen prior
CH to diagnosis (%)
Migraine 51.0 Primary care physician 63.5
Trigeminal neuralgia 42.3 Dentist 25.9
Ophthalmic disease 11.0 ENT specialist 35.5
Dental or jaw disease 15.1 Ophthalmologist 31.4
ENT disease 25.1 Neurologist 41.3
Cervical spine disease 12.0 Neurosurgeon 8.5
Other 22.6
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lithium for prevention (Table 11). In addition, a substantial
proportion was offered treatment with carbamazepine,
flunarizine, antidepressants or alternative treatments. Use of
recommended treatments, such as sc sumatriptan, O2 inhal-
ation, corticosteroids or verapamil did not seem to be much
more common even among previously diagnosed patients
who had been diagnosed by a neurologist (Table 11).
Discussion
Although less common than other primary headaches,
cluster headache is not rare per se [9, 12, 13]. Still, world-
wide it is reported to remain largely under-recognized and
sub-optimally or poorly treated both in primary care and
by specialists, despite the fact that its severity would war-
rant prompt diagnosis and treatment [7, 12, 18–21, 30].
Therefore, it is critical that all physicians be familiar with
diagnosing and managing cluster headache. In order to
improve recognition and successful treatment of CH by
Greek neurologists and general physicians, we undertook
the task of describing the demographic, clinical characteris-
tics, diagnostic and treatment paths of a large cohort of CH
patients, seen over a lengthy period of time by the same
headache specialist.
Overall, our data are in line with previously published
data from different countries [5, 7, 14–17, 31]. As
expected, the typical presentation of cluster headache in
Greece is indisputably stereotyped and distinct from
other primary headache syndromes. Still, our data show
that CH is not a male disorder, as the female to male
ratio for patients with disease onset during this decade
has fallen to 2.3:1 from 6:1 twenty years ago, a finding
that has been noticed long ago [32]. Clinical presenta-
tion of the disease was largely similar in both genders.
Features often considered uncommon or atypical were
encountered in a significant percentage of patients in
our cohort. Those included side shifts, maximal pain in-
tensity outside the first division of the trigeminal nerve,
lack of all autonomic features or lack of a sense of rest-
lessness or agitation, as other studies have also shown
[5, 7, 16, 33]. Some of the atypical features, including
side shifts, pain located in jaw, cheek, teeth, shoulder,
vertex or neck area, were found in our study to be coex-
istent with, and maybe the cause of, delayed diagnosis
and/or a larger number of physicians being consulted
prior to diagnosis. In addition, migraine associated
symptoms and autonomic features were often encoun-
tered, with photophobia being the most common, but
not the only one reported in our series. This is in line
with previously published data [7, 34, 35]. In our cohort,
among migraine associated symptoms, aggravation by
physical activity, reported by 10 % of our patients, was
related both to delayed diagnosis and a greater number
of physicians being consulted prior to diagnosis. It is
worth mentioning that even though the autonomic fea-
tures added in criterion C of the revised criteria of the
International Headache Society (ICHD-III beta) for CH,
(−namely ipsilateral sensation of fullness in the ear and
ipsilateral forehead/facial flushing) were rather com-
monly reported in our group, there was not a single case
of a patient without the presence of any of the auto-
nomic features included in ICHD-II (conjunctival injec-
tion and/or lacrimation, nasal congestion and/or
rhinorrhea, eyelid oedema, forehead and facial sweating)
in whom forehead and facial flushing or sensation of
fullness in the ear was reported. This supports the opin-
ion that adding forehead and facial flushing and
Table 9 Factors correlated with more years to diagnosis
Years to diagnosis
Median (Range) p-value
Decade of onset 0.001
< 2000 13 (0–45)
2000–2009 5 (0–14)
≥ 2010 1 (0–7)
Side shift between bouts 0.008
No 5 (0–45)
Yes 8 (0–26)
Jaw location of pain 0.002
No 5 (0–30)
Yes 7 (0–45)
Cheek location of pain 0.015
No 5 (0–30)
Yes 7 (0–45)
Lower teeth location of pain 0.015
No 5 (0–30)
Yes 10 (0–45)
Ear location of pain 0.041
No 5 (0–41)
Yes 10 (0–45)
Photophobia 0.016
No 4 (0–30)
Yes 6 (0–45)
Aggravation by physical activity 0.008
No 3 (0–20)
Yes 6 (0–45)
Forehead and facial sweating 0.018
No 5 (0–30)
Yes 6 (0–45)
Absence of autonomic features 0.023
No 2 (0–14)
Yes 5 (0–45)
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sensation of fullness in the ear in ICHD-III beta provides
no added diagnostic value [36].
Concerning diagnostic delays, our data are in line with
other published studies, which have already shown that CH
patients are often misdiagnosed and mistreated [7, 19, 20,
30, 37]. In our cohort, eight out of ten CH patients have
consulted at least one physician without been diagnosed
and more than 40 % have consulted a neurologist. Further-
more, even in diagnosed patients, and despite the existence
of evidence-based treatment options [10, 13, 22–26, 37, 38],
use of guidelines or recommended treatments is quite low.
These facts clearly point out the need for Continuous
Medical Education in the field of cluster headache. Still, our
study demonstrates that time to diagnosis is improving in
Greece, something that might have to do with increasing
access to specialized neurologic care and headache special-
ists. The role of medical information found mainly on the
internet is increasingly important, as a significant percent-
age of patients in our group, despite having seen physicians,
were actually self-diagnosed and self-referred to our center.
In addition, despite these improvements, the typical sufferer
still waits five years for a correct diagnosis and sees three
Table 10 Factors correlated with seeing increased number of
physicians prior to diagnosis
Median (Range) p-value
Number of physicians
CH subtype 0.001
ECH 2 (0–15)
CCH 4 (0–15)
Decade of onset 0.001
< 2000 5 (0–15)
2000–2009 3 (0–11)
≥ 2010 1 (0–10)
Upper teeth location of pain 0.001
No 3 (0–15)
Yes 4 (0–15)
Jaw location of pain 0.001
No 3 (0–15)
Yes 4 (0–15)
Cheek location of pain 0.001
No 2 (0–15)
Yes 5 (0–15)
Lower teeth location of pain 0.002
No 3 (0–15)
Yes 5 (0–15)
Neck location of pain 0.001
No 3 (0–15)
Yes 5 (0–15)
Nose location of pain 0.007
No 3 (0–15)
Yes 5 (0–15)
Ear location of pain 0.001
No 3 (0–15)
Yes 5 (1–15)
Shoulder location of pain 0.001
No 3 (0–15)
Yes 8 (1–11)
Vertex location of pain 0.036
No 3 (0–15)
Yes 4 (0–10)
Aggravation by physical activity 0.024
No 2 (0–10)
Yes 3 (0–15)
Eyelid oedema 0.024
2 (0–10) 3 (0–15)
2 (0–10) 4 (0–15)
Table 10 Factors correlated with seeing increased number of
physicians prior to diagnosis (Continued)
Miosis and/or ptosis 0.001
2 (0–10) 2 (0–15)
2 (0–10) 4 (0–15)
Spearmans’ rho
Usual maximum duration of bout 0.208 0.001
Usual duration of bout 0.224 0.001
Usual attack frequency 0.220 0.001
Usual maximum attack frequency 0.310 0.001
Table 11 Treatments offered to previously diagnosed patients, (%)
Overall %
(N = 127)
Previously diagnosed by a
neurologist % (N = 89)
Subcutaneous sumatriptan 2.4 3.4
O2 inhalation 13.5 13.5
Triptans orally 31.0 33.7
Corticosteroids orally 43.7 44.9
Verapamil 18.3 20.2
Lithium 3.2 2.2
Topiramate 23.8 23.6
Valproate 6.3 6.7
Carbamazepine 18.3 15.7
Flunarizine 16.7 19.1
Tricyclic antidepressants 10.3 9.0
SSRIs, SNRIs 11.1 10.1
Alternative treatments 28.2 32.2
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physicians prior to it, having received one or more incorrect
diagnoses, inappropriate treatments or having undergone
unnecessary invasive procedures, as has also been described
in other series [19–21].
This study does not come without limitations. The main
one is the design of the study and the setting. It could be
argued that a population-based study, resulting in a ran-
dom sample of CH patients would be more appropriate
and that CH patients who reach a specialist may represent
an enriched population who would have atypical features
or be more difficult to treat correctly. We believe our data
do not point towards a highly enriched population.
Patients visited us from all geographical regions of Greece,
most patients came through self-referral (84.7 %), some-
thing quite common in Greece. Additionally, the majority
of our cohort (57.9 %) were undiagnosed prior to visiting
our clinic. Furthermore, extrapolating from the inter-
national CH prevalence data [9] to the Greek population
(10.816.286 according to the last census) [39], an estima-
tion of around 13.400 CH patients are expected to live in
Greece. In this case, our sample would represent a little
more that 2 % of the total CH patients in Greece.
Conclusions
Cluster headache, studied in a large cohort of Greek
patients, has the well-documented general characteristics
described in all Western populations. Despite the concept
of a stereotyped clinical picture, atypical features are quite
often present and physicians should be aware of those, as
they usually may result in diagnostic problems. Most
patients remain undiagnosed for a lengthy period of time;
even when diagnosed, the treatment they receive remains
far from optimal. On the other hand, our data show that
time to diagnosis is improving, reaching a median period
of one year for patients with recent onset. Educational
activities for neurologists and other medical specialties
that treat headache patients are critically important and
should result in better recognition and treatment of
cluster headache patients.
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